Laurion Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Laurion Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-227,022	Closed	-$2.07M	–	747
2022 Q1	$2.07M	Buy	+227,022	New	+$1.75M	0.03%	210
2019 Q2	–	Sell	-38,966	Closed	-$1.85M	–	1259
2019 Q1	$1.85M	Buy	+38,966	New	+$1.72M	0.02%	343
2017 Q4	–	Sell	-4,800	Closed	-$233K	–	1941
2017 Q3	$233K	Buy	+4,800	New	+$262K	﹤0.01%	1396
2017 Q2	–	Sell	-5,500	Closed	-$249K	–	1943
2017 Q1	$249K	Buy	+5,500	New	+$245K	﹤0.01%	1124
2016 Q4	–	Sell	-24,300	Closed	-$917K	–	1338
2016 Q3	$917K	Buy	+24,300	New	+$536K	0.01%	583
2016 Q1	–	Sell	-9,900	Closed	-$241K	–	1186
2015 Q4	$241K	Buy	+9,900	New	+$231K	﹤0.01%	781

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Laurion Capital Management's AERI Position: Q2 2022 in Review

Laurion Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2022, closing a stake of 227,022 shares — an estimated $2.07M sold.

Laurion Capital Management first reported a position in AERI in Q4 2015 and held it in 6 quarters. The position peaked at $2.07M in Q1 2022. 137 funds tracked by Wall St. Rank hold AERI as of Q2 2022.

Laurion Capital Management reported no remaining Aerie Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Laurion Capital Management sold 227,022 Aerie Pharmaceuticals shares in Q2 2022, an estimated $2.07M.
Laurion Capital Management first reported a position in Aerie Pharmaceuticals in Q4 2015 and held it in 6 quarters.
Laurion Capital Management's Aerie Pharmaceuticals position peaked at $2.07M in Q1 2022.
137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.